In contrast, in MCL, inhibition of NLRP3 inflammasome activation or blockade of IL-1β signaling with agents such as Anakinra or Canakinumab could attenuate the exaggerated inflammatory response [42,43,44]. The gene discussed is NLRP3; the disease is mantle cell lymphoma.